VolitionRx Ltd. (NYSE American: VNRX), a multi-national epigenetics company, provided a consolidated update highlighting recent clinical and commercial progress across its key platforms. The company emphasized the submission of a manuscript for peer review that showcases a new method, Capture-Seq, and new biomarkers for the detection of cancer, which it estimates represents an annualized total addressable market opportunity of approximately $23 billion.
Commercialization of the Nu.Q Cancer assay progressed in lung cancer, with the company reporting that reimbursement submission in France is on track, and routine clinical use is expected by Q4 2026. Volition also confirmed the inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis, and highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting CE-marked availability across Europe.
The company also reported breakthrough veterinary results demonstrating 100% specificity in detecting feline lymphoma using its Nu.Q Vet Feline assay. Volition said publication of the feline study is expected to unlock a $5 million contractual milestone payment. Additionally, Volition confirmed ongoing licensing discussions with approximately 10 global diagnostic leaders and stated it anticipates announcing additional licensing agreements during 2026.
These developments underscore Volition's progress in advancing its epigenetic-based diagnostic platforms across multiple disease areas. The Capture-Seq method and new biomarkers represent a significant expansion of the company's capabilities, targeting a large market opportunity. The progress in lung cancer commercialization, sepsis detection, and veterinary diagnostics demonstrates the breadth of Volition's pipeline.
For more details, the full press release is available at https://ibn.fm/rgAob.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. For further information, visit the company’s website at www.Volition.com.
